| Dr Mark Daniel Bouchard, MD | |
|
751 Ne Blakely Dr Ste 5010, Issaquah, WA 98029-6201 | |
| (425) 394-0700 | |
| (425) 394-0757 |
| Full Name | Dr Mark Daniel Bouchard |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 751 Ne Blakely Dr Ste 5010, Issaquah, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316392517 | NPI | - | NPPES |
| 1316392517 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD61046264 (Washington) | Primary |
| Entity Name | Sun River Health Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568526838 PECOS PAC ID: 6608783568 Enrollment ID: O20040714000375 |
News Archive
Patients hospitalized with COVID-19 were more likely male, younger, and, in both the US and Spain, had fewer comorbidities and lower medication use than hospitalized influenza patients according to a recent study published by the Observational Health Data Sciences and Informatics community.
Human skin cells can be converted directly into functional neurons in a period of four to five weeks with the addition of just four proteins, according to a study by researchers at the Stanford University School of Medicine.
SoftVue, the whole breast ultrasound imaging device created by two scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for market clearance.
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.
The U.S. Department of Housing and Urban Development is threatening to halt federal funding for the Washington D.C.'s AIDS programs after a Washington Post investigation found many delivered faulty services and failed to account for their work.
› Verified 2 days ago
| Entity Name | North Shore - Lij Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053688572 PECOS PAC ID: 3375701568 Enrollment ID: O20120220000262 |
News Archive
Patients hospitalized with COVID-19 were more likely male, younger, and, in both the US and Spain, had fewer comorbidities and lower medication use than hospitalized influenza patients according to a recent study published by the Observational Health Data Sciences and Informatics community.
Human skin cells can be converted directly into functional neurons in a period of four to five weeks with the addition of just four proteins, according to a study by researchers at the Stanford University School of Medicine.
SoftVue, the whole breast ultrasound imaging device created by two scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for market clearance.
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.
The U.S. Department of Housing and Urban Development is threatening to halt federal funding for the Washington D.C.'s AIDS programs after a Washington Post investigation found many delivered faulty services and failed to account for their work.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Daniel Bouchard, MD Po Box 25608, Salt Lake City, UT 84125-0608 Ph: (206) 320-4476 | Dr Mark Daniel Bouchard, MD 751 Ne Blakely Dr Ste 5010, Issaquah, WA 98029-6201 Ph: (425) 394-0700 |
News Archive
Patients hospitalized with COVID-19 were more likely male, younger, and, in both the US and Spain, had fewer comorbidities and lower medication use than hospitalized influenza patients according to a recent study published by the Observational Health Data Sciences and Informatics community.
Human skin cells can be converted directly into functional neurons in a period of four to five weeks with the addition of just four proteins, according to a study by researchers at the Stanford University School of Medicine.
SoftVue, the whole breast ultrasound imaging device created by two scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for market clearance.
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.
The U.S. Department of Housing and Urban Development is threatening to halt federal funding for the Washington D.C.'s AIDS programs after a Washington Post investigation found many delivered faulty services and failed to account for their work.
› Verified 2 days ago
Linda S Hung, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1011 Ne High Street, Suite #200, Issaquah, WA 98029 Phone: 425-391-7337 Fax: 425-391-3915 | |
Haejun Cecilia Ahn, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 751 Ne Blakely Dr Ste 5010, Issaquah, WA 98029 Phone: 425-313-7088 Fax: 425-394-0757 | |
Kathrine Ryan, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1011 Ne High Street, Suite #200, Issaquah, WA 98029 Phone: 425-391-7337 Fax: 425-391-3915 | |
Troy Yi, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 6520 226th Pl Se Ste 100, Issaquah, WA 98027 Phone: 425-394-1680 Fax: 425-394-1674 | |
Tracie O'neill, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1011 Ne High Street, Suite #200, Issaquah, WA 98029 Phone: 425-391-7337 Fax: 425-391-3915 | |
Mrs. Tiffany Lynne Herr, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 751 Ne Blakely Dr Ste 5010, Issaquah, WA 98029 Phone: 425-394-0701 | |
Dr. David Ege, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 450 Nw Gilman Blvd Ste 201, Issaquah, WA 98027 Phone: 425-391-0705 Fax: 424-391-9562 |